Skip to main content

HubXchange

HubXChange logo

Advanced Therapies Xchange - San Francisco - 2026

Page Banner 1

    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Spotlight Presentation:
  2. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Poster Presentation: Transient vs Stable Cell Lines for AAV Manufacturing: A Cost Modelling Approach
  3. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    How can lipid nanoparticles, exosomes, and hybrid systems compete with or complement viral vectors for in vivo delivery?
  4. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Bridging Next‑Generation Capsid Innovation and Manufacturability: Aligning Research and CMC for Clinical Readiness
  5. Cell Therapy Manufacturing
    • Cell Therapy Manufacturing
    Poster Presentation: Automation and digital QA systems in cell therapy manufacturing
  6. Gene Therapy Manufacturing
    • Gene Therapy Manufacturing
    Upstream strategies to reduce empty capsid formation
  7. Gene Therapy Manufacturing
    • Gene Therapy Manufacturing
    Poster Presentation: Integration of digital systems and automation in vector manufacturing and QC
  8. Cell Therapy Manufacturing
    • Cell Therapy Manufacturing
    Scaling cell therapy manufacturing without compromising quality: Rethinking compliance, digitalization, and GMP
  9. Gene Therapy Development
    • Gene Therapy Development
    What are the most effective strategies to predict and mitigate immune responses to gene therapies, both in preclinical and early clinical stages?
  10. Cell Therapy Development
    • Cell Therapy Development
    Process robustness and product consistency in  PSC-derived cell therapy development
  11. Cell Therapy Manufacturing
    • Cell Therapy Manufacturing
    Advancing CMC for autologous cell therapies: building robust, scalable platforms
  12. Gene Therapy Development
    • Gene Therapy Development
    Advancing purity in AAV gene therapy: strategies for minimizing and clearing empty capsids
  13. Gene Therapy Development
    • Gene Therapy Development
    How can we enhance AAV, LV, and non-viral delivery technologies to increase efficiency, tissue targeting, and reduce immunogenicity?
  14. Gene Therapy Manufacturing
    • Gene Therapy Manufacturing
    GMP-compliant viral vector production: scale-up, reproducibility, and quality control
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Afternoon Refreshments
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Morning Refreshments
  17. Cell Therapy Manufacturing
    • Cell Therapy Manufacturing
    Validation strategies for novel CNS targets: From molecular mechanism to therapeutic candidate
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Evening Drinks Reception
  19. Cell Therapy Development
    • Cell Therapy Development
    Poster Presentation: Translational challenges in predictive preclinical models
  20. Gene Therapy Development
    • Gene Therapy Development
    Poster Presentation: How can circulating biomarkers, genomic integration assays, or functional assays better predict efficacy and long-term safety in patients?
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    1-2-1 Meetings / Networking Break
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    1-2-1 Meetings / Networking Break
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Spotlight Presentation:
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Networking Lunch
  25. Cell Therapy Development
    • Cell Therapy Development
    Potency and safety considerations for iPSC-derived cell products
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    1-2-1 Meetings / Networking Break
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    1-2-1 Meetings / Networking Break
  28. Gene Therapy Manufacturing
    • Gene Therapy Manufacturing
    Analytical testing strategies for gene therapy: GMP release testing, stability testing and comparability assessments
  29. Cell Therapy Development
    • Cell Therapy Development
    Overcoming challenges hindering potency within the tumour microenvironment to enhance the efficacy of cell therapies for solid tumours
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Opening Address & Keynote Presentation:
    • Next Gen Vector Engineering & Delivery
    • Cell Therapy Development
    • Cell Therapy Manufacturing
    • Gene Therapy Development
    • Gene Therapy Manufacturing
    Registration
Search